Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it
will highlight new innovations at the American College of Foot and
Ankle Surgeons (ACFAS) 2018 Scientific Conference taking place at
the Gaylord Opryland Hotel in Nashville, Tennessee, from March
22-25, 2018.
Wright will feature its full range of lower
extremities and biologic solutions at exhibit booth #244, including
the INVISION™ Total Ankle Revision System with PROPHECY
Preoperative Navigation, the first preoperative planning system
with patient-specific instrumentation for ankle revision
arthroplasty. The introduction of INVISION with PROPHECY is
an important addition to Wright’s total ankle portfolio, extending
the use of preoperative planning to the entire continuum of care
from primary through revision procedures.
“The INVISION Total Ankle Revision System with
PROPHECY Preoperative Navigation builds on Wright Medical’s
commitment to providing physicians with innovative tools that lead
to the best possible patient outcomes,” said Robert Palmisano,
President and Chief Executive Officer of Wright. “Total ankle
arthroplasties provide a unique set of challenges for our
physicians and we are excited to be bringing this technology to
market to see its success in action. The launch of INVISION
with PROPHECY expands our leadership in total ankle technology and
marks our ability to best address the total ankle replacement
continuum of care.”
The PROPHECY System was first approved for total
ankle replacement in 2012 and has been clinically proven to help
surgeons accurately align ankle replacements1 and increase surgical
efficiency by reducing OR time and potentially cost2.
Developed from the patient’s own CT scan, implant sizing and
alignment are determined using the patient’s unobstructed anatomic
landmarks and the surgeon’s preferences. PROPHECY alignment guides
are subsequently created, providing patient-specific instruments to
help the surgeon precisely position implants while reducing
surgical steps, which in turn allows for less procedural complexity
and surgery time.
“Revision of a failed total ankle arthroplasty
remains a challenge,” said Dr. William McGarvey, Chief of Foot and
Ankle Surgery at the McGovern Medical School at the University of
Texas Health Science Center – Houston, who has performed several
revision procedures with PROPHECY to date. “The ability to
preoperatively plan out these cases and determine appropriate
alignment based on the individual patient’s CT data will provide
surgeons with an extra level of confidence that the implants will
be positioned in the optimal alignment.”
Key benefits of PROPHECY now include:
- Full array of implant choices (INFINITY™, INBONE™ or INVISION™)
to fit the patient’s specific needs
- Ability to create a detailed revision surgical plan with or
without failed implants currently in place
- 3D visualization of how to manage bone loss and reconstruct
joint height under unique revision conditions
Recent new products to be featured at ACFAS
include:
INVISION™ Total Ankle Revision
System – The first and only system developed specifically
for total ankle revision arthroplasty, the INVISION Total Ankle
Revision System provides a unique solution for even the most
difficult revision procedures. Whether leveraged as a standalone
construct or in conjunction with INFINITY and INBONE components,
the INVISION Total Ankle Revision System is an important addition
to the continuum of care from total ankle replacement through any
necessary revisions. The INVISION Total Ankle Revision System helps
surgeons re-build bone lost through previous surgeries and provides
modularity to help restore natural joint height.
ORTHOLOC™ 3Di Ankle Fracture Low Profile
System – The ORTHOLOC 3Di Ankle Fracture Low Profile
System features a complete range of ankle fracture plates designed
specifically for the foot and ankle surgeon. The system features
low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial
locking screw technology, providing an innovative fracture solution
that addresses a primary need for one of the foot and ankle’s
largest market segments.
For more information about Wright Medical’s
portfolio of total ankle products,
visit: www.totalankleinstitute.com
1 Hsu AR, Davis WH, Cohen BE, Jones CP,
Ellington JK, Anderson RB. Radiographic outcomes of preoperative CT
scan-device patient-specific total ankle arthroplasty. Foot Ankle
Int 2015;36:1163-1169.2 Hamid KS, Matson AP, Nwachukwu BU, Scott
DJ, Mather RC, DeOrio JK. Determining the cost-savings threshold
and alignment accuracy of patient-specific instrumentation in total
ankle replacements. Foot Ankle Int 2016;38:49-57.
Internet Posting of
Information
Wright routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.wright.com. The company encourages investors
and potential investors to consult the Wright website regularly for
important information about Wright.
About Wright Medical Group
N.V.
Wright Medical Group N.V. is a global medical
device company focused on extremities and biologics products.
The company is committed to delivering innovative, value-added
solutions improving quality of life for patients worldwide and is a
recognized leader of surgical solutions for the upper extremity
(shoulder, elbow, wrist and hand), lower extremity (foot and ankle)
and biologics markets, three of the fastest growing segments in
orthopedics. For more information about Wright, visit
www.wright.com.
Cautionary Note Regarding
Forward-Looking Statements
This release includes forward-looking statements
under the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this release include, but are not
limited to, statements about the performance and market acceptance
of the company’s products. Forward-looking statements by their
nature address matters that are, to different degrees, uncertain.
Each forward-looking statement contained in this release is subject
to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such
statement. Applicable risks and uncertainties include, among
others, physician acceptance, endorsement, and use of company
products; the effect of regulatory actions, changes in and adoption
of reimbursement rates; product liability claims; product recalls;
the effects of industry, economic or political conditions outside
of the company’s control; competitor activities; and the risks
identified under the heading “Risk Factors” in Wright’s Annual
Report on Form 10-K for the year ended December 31, 2017 filed by
Wright with the SEC on February 28, 2018 and in other subsequent
SEC filings by Wright. Investors should not place considerable
reliance on the forward-looking statements contained in this
release. Investors are encouraged to read Wright’s filings with the
SEC, available at www.sec.gov, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this
release speak only as of the date of this release, and Wright
undertakes no obligation to update or revise any of these
statements. Wright’s business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Investors & Media:
Julie D.
Tracy
Sr. Vice President, Chief Communications
OfficerWright Medical Group N.V.(901)
290-5817julie.tracy@wright.com
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Apr 2023 to Apr 2024